… -term safety of indacaterol from a study … indacaterol, 150 or 300 μg, or placebo once daily
for a further 26 weeks. The primary objective was to evaluate the 52-week safety of indacaterol; …

… demonstrates that the novel once-daily β 2 -agonist indacaterol is well tolerated at doses up
… support the previously demonstrated 24-h bronchodilator efficacy of once-daily indacaterol. …

… to investigate the 24-hour profile of bronchodilator efficacy of single doses of indacaterol,
400 μg, via single-dose dry powder inhaler (SDDPI) and indacaterol, 200 μg, via multidose dry …

… , indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action.
This study compared the efficacy and safety of indacaterol … was that indacaterol would have a …

… To compare the efficacy and safety of indacaterol versus placebo and alternative twice‐daily
long‐acting beta 2 ‐agonists for the treatment of patients with stable COPD. …

… demonstrated that single doses of indacaterol provide 24-hour … When administered once
daily for 28 days, indacaterol is … the efficacy and safety of multiple doses of indacaterol (100, 200…

… A oncedaily β2-agonist bronchodilator, indacaterol, was … evaluation of the efficacy and
safety of indacaterol and include … The objective of this paper is to review the efficacy of this new …

… In vitro studies during the preclinical development of indacaterol Citation13 characterized
this new agent as having high agonist efficacy at the human β2-adrenoreceptor, with a binding …

… Indacaterol is a beta2-agonist with high intrinsic efficacy at the receptor level. In preclinical
and in-vitro models it behaves like an almost full agonist … Potency and intrinsic efficacy have …

… FEV 1 ) between indacaterol and placebo 30 … indacaterol 200 and 400 µg meeting pre-specified
efficacy criteria. The mean percentage increases in FEV 1 from placebo with indacaterol …